The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz

• https://ard.bmj.com/content/80/Suppl_1/140.full

Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021 https://t.co/S0ownscRKv https://t.co/PJODe0U6wr

• Turning the Corner on CV Risk in Rheumatoid Arthritis | RheumNow

"The concept of JAK selectivity is based on in vitro assays, with limited impact on cellular and clinical aspecrts of the use of JAK inhibitors" - Hendrik Schulze-Koops, @LMU_Muenchen #EULAR2021 @RheumNow

So what does JAK selectivity actually mean? How selective is selective? Hendrik Schulze-Koops #EULAR2021 @RheumNow https://t.co/Oh8wZCKcSj

A biosimilar to placebo! #POS0276 study eval krill oil for knee pain. 452 participants randomized to krill oil 2 g/d X 24 wks. no difference in knee pain function, lipids, inflammation, leg strength or adverse events #EULAR2021 @rheumnow https://t.co/cajz6sfhzn

Exercise won't flare your disease #POS0404 Study of DBA/1 RA prone mice compared: exercised vs. not mice that exercised: - did NOT have⬆️in IL6, TNFa, IL17A - had⬇️levels of sclerostin - did NOT get enthesial mineralizat'n #EULAR2021 @rheumnow https://t.co/REP2UKp7Ci

JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr

Dr Mulhearn presents that excess GCA cases are associated with COVID-19 peaks. Annual incidence rate of 13.7/100,000 in 2019 and 29.8/100,000 in 2020. Interesting, needs replication! @RheumNow #EULAR2021 Abstr#OP0281 https://t.co/kDk7ARnxMn

Enthesitis response to SEC over 24w in PsA pts from ULTIMATE? ➡️ULTIMATE: 52w DB, PIII RCT that showed sign impr of synovitis (PDUS-detected) w/ SEC vs PBO in pts w/ PsA ➡️OP0226: SEC improved enthesitis at wk 12 & 24 per SPARCC & Global OMERACT-US scores #EULAR2021 @RheumNow https://t.co/QiCo4CVHz3

Can we identify #SLE patients who cd benefit from earlier bDMARDs? Dr Hassan showed 105/209(50%) pts required bDMARDs/Cyclophosphamide. Time-to-therapy was associated with⬇️C3/C4 and⬆️cSLEDAI-2K. More works needed re: biomarkers & varied population #EULAR2021 #POS0175 @RheumNow https://t.co/gK7Ew3WJUj

Sentinel joint! #POS0385 Study of 524 preclinical RA followed 2 yrs found that intermetatarsal bursitis (IMB) can predict devl't of RA esp in ACPA+ pts 👉>70% w/abnormal IMB dev RA over 1 yr 👉synovial lining is found in the intermetatarsals #EULAR2021 @rheumnow https://t.co/RQzZRh1eC2

Do you think that JAK1 selectivity matters in rheumatological clinical practice? #EULAR2021 @RheumNow

Does vit D level predict response to RA Rx? Yes...maybe! POS0100 showed in 236 RA pts, 57% starting TNFi, rest other bDMARDs, at 1 yr, good responders & remission 4x less likely to respond if low vit D but sig for DAS(ESR) not CDAI/SDAI. ?Give VIT D to all! #EULAR2021 @RheumNow

"PsA is the most common co-morbidity in pediatric PsO patients (OR - 5.3), the second is obesity." Dr. Yonathan Butbul. It is estimated that 1/3 of PsO pts will have juvenile disease onset, but may not be diagnosed until adulthood. #EULAR2021 @RheumNow